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ABSTRACT 
During the past decades, epilepsy syndrome has been depicted across India as well as worldwide and this leads to increasing mortality and 
morbidity rate. Researchers are trying to investigate the responsible causes and risk factors for seizure occurrence. Epilepsy is a chronic 
disorder which is derived from a Latin word ‘sacire’ meaning ‘convulsive attack’ and is expressed as a paroxysmal experience appointed to 
atypical, unnecessary or concurrent neuronal bustle in the brain. The treatment of epilepsy involves the use of anti-epileptic drugs i.e. Sodium 
valproate, phenytoin, carbamazepine. Despite being treated with the available anti-convulsant drugs, this disease is still prevalent worldwide. So, 
as an adjuvant treatment melatonin exhibit an anti-epileptic activity in several animal models of epilepsy. However, its anti-epileptic potential 
has yet to be evaluated in Pentylenetetrazole (PTZ) induced model of epilepsy through kindling phenomenon. Rats were injected with a dose of 
(35-55 mg/kg) of pentylenetetrazole (PTZ) up to twenty days in alternate days. Observed the convulsive behavior of rats for thirty minutes 
immediately after PTZ injection.  The entire treatment schedule includes the administration of melatonin (75 mg/kg) one hour prior to the PTZ 
administration. Sodium valproate was used as standard drug for this kindling model of epilepsy. 
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1. INTRODUCTION  
Epilepsy is considered as one of the most prevailing 
pandemic of the twenty-first century1 (Ben et al. 2009). 
According to the World Health Organization report, around 
fifty million people worldwide are suffering from epilepsy 
syndrome2,3. It has been suggested that the epilepsy leads to 
several complications4 including central nervous system 
disorders5,6  result from the complex interaction between 
epileptogenic, precipitating and endogenous factors.  
Various clinical and animal studies revealed that epilepsy 
can cause multidimensional cognitive impairment. The 
treatment of epilepsy involves the use of anti-epileptic drugs 
i.e. Sodium valproate, phenytoin, carbamazepine7. It has 
been documented that sodium valproate can ameliorate γ-
amino butyric acid level in epileptic animals8. However, 
along with their efficacy and potency, several adverse effects 
of sodium valproate have also been reported including 
abdominal cramps, abnormal liver function, and tremor9,10. 
Hence, it is imperative to discover novel strategies in the 
management of epilepsy syndrome.  
Melatonin is considered as hormone of darkness as well as 
human time keeping machine. It accomplishes clock and 
calendar functions to make the human body alter to diurnal 
variation which impact the 24-h rhythms in physiology and 
behaviors of human body11,12. Lerner and his colleagues 
worked on melatonin by isolating and chemically 
characterizing them from mammalian pinealocytes in 
195813. Melatonin (also called pleiotropic hormone) exhibit 
chronobiotic effects linked with hormonal secretion, sleep-
wake cycle, thermoregulation and other physiological 
events14-16. Melatonin have also been observed to maintain 
the immunity, energy metabolism, feeding behavior, free 
radical scavenging, cancer proliferation, maintenance of 
vasculature, inflammation, reproduction growth and 
development17. 
Melatonin also exhibits anti-epileptic activity against 
experimentally induced epilepsy in several animal models. 
Moreover, it has been reported that melatonin can protect 
neuronal damage in the brain of chemical-induced epileptic 
animals. 
Several epidemiological studies have postulated that 
neuronal hyperexcitability is the main reason in the 
pathogenesis of epileptic seizure. Underlying molecular 
mechanism of rapid neuronal firing, it depends on three 
steps which include decreased inhibitory neurotransmission, 
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increased excitatory neurotransmission, and variation in 
sodium or potassium ion channels18-19 Glutamate20-22, GABA, 
Dopamine, Serotonin, Acetylcholine are some major 
neurotransmitters found in central nervous system23 (Nicoll 
et al. 1990). Among them, GABA and glutamate (inhibitory 
and excitatory neurotransmitter respectively) are the 
important neurotransmitters for the mechanism of 
epilepsy24,25.  Experimental result suggests that melatonin 
increases the seizure threshold by enhancing the GABA level 
in the hippocampus region of the central nervous system. 
Inhibitory neurotransmitter (GABA) precedes their effects 
through GABAA and GABAB receptors, which are found 
postsynaptically and presynaptically respectively26-28. 
Melatonin exerts their effect by opening the chloride 
channels through the activation of GABA-A receptors which 
leads to inhibition of action potential and thus effective in 
epilepsy syndrome29-31. 
2. MATERIAL AND METHODS 
2.1. Animals 
Male Wistar albino rats (180 ± 20 g) were obtained from the 
central animal house, Institute of Pharmaceutical Research, 
GLA University, Mathura and were used in this study. The 
animals were grouped and housed in poly-acrylic cages lined 
with husk under standard conditions (24 ± 2 °C temperature, 
45–55 % relative humidity and 12 h light: 12 h dark cycle). 
Animals were fed standard pellets diet and had free access to 
water. The experimental protocol was carried out in 
accordance with the approval of the Institutional Animal 
Ethics Committee (1260/Po/ac/09/CPCSEA/IAEC/2018/ 
P.Col./R01) under strict compliance of the Committee for the 
Purpose of Control and Supervision of Experiments on 
Animals (CPCSEA) guidelines for experimental studies 
(National Research Council US Committee for the update of 
the guide for the care and use of laboratory animals 2011)32. 
2.2. Chemicals 
Melatonin was purchased from Central Drug House, India. 
Curcumin (Yarrow chemicals), Sodium valproate (Yarrow 
chemicals), Pentylenetetrazole (Star chemicals) and GABA 
(yarrow chemicals). All other chemicals and reagents were 
available commercially from local suppliers and were of 
analytical grade. 
2.3. Animal Kindling Model of Pentylenetetrazole 
induced epilepsy 
Rats were injected intra-peritoneally with sub convulsive 
doses of Pentylenetetrazole at 48 h intervals during 20 days 
(From 35 mg/kg to 55 mg/kg) [additional 5mg after each 2 
injections]33. 
2.4. Experimental Design 
The acclimatized animals were divided into three groups of 
six rats in each. Each groups namely control, Test drug and 
standard. All the animals received Pentyleneterazole (PTZ) 
(except control) in an alternative manner for up to 20 days. 
Assessment of convulsion behavior in rats immediately after 
the PTZ injection for 30 minutes and scored according to 
modified Racine’s scale34.  
2.5.  Assessment of Behavioral parameters 
According to researchers, seizure scores are evaluated under 
the following headings: 
 
Table 1: Seizure scores in accordance with modified  Racine’s scale 
Behavioral Responses Scores 
No seizure 0 
Sudden immobilization 1 
Ear and facial twitching 2  
Facial, vibrissal and forelimb clonus/or wet dog shake behavior 3 
Sporadic forelimb clonus with kangaroo posture 4 
Clonic and/or tonic seizures with posture maintenance  5 
Generalized tonic-clonic seizures with loss of posture tone, and turning onto the 
side and seizures characterized by rearing and falling 
6 
Death within half an hour 7 
           
PTZ administration was withdrawn after establishment of 
kindling status and subsided by saline injections until the 
end of the protocol. After the induction of epilepsy, the 
treatment schedule involves the administration of test drug 
(melatonin 50 mg/kg) and standard drug (sodium valproate, 
200 mg/kg) through oral route one hour prior to the 
administration of Pentylenetetrazole. 
 
Figure 1: Graphical representation of induction of seizure 
during kindling progression according to Racine’s seizure 
scale 
2.6. Data Analysis 
All the data were mean ± standard error of the mean (SEM). 
All statistical analyses of data were done using one-way 
analysis of variance (ANOVA) with Dunnett multiple 
comparison test. P< 0.05 was considered as *significant; P< 
0.01 was considered as **more significant. 
3. RESULTS 
Table depicts the effect of melatonin (75 mg/kg) on PTZ 
induced changes in the level of γ-amino butyric acid (GABA). 
Stastical analysis revealed that melatonin treatment 
significantly attenuated PTZ induced decrease in the levels of 
GABA in wistar albino rats. However, the anti-epileptic 
activity of melatonin (75 mg/kg) was significantly lower 
compared to standard drug sodium valproate in epileptic 
rats Table-2. 
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Table 2: Drug concentration 
Groups   Concentration  
Control   76 ± 2.531 
Test  drug (Melatonin)   112 ± 2.312** 
Standard drug (Sodium Valproate)   120 ± 2.112** 
All values are mean ± SEM (n = 6) 
 
(One way ANOVA followed by Dunnett multiple comparison 
test). ** More Significant difference at P< 0.01 vs. Control 
group. 
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Figure 2: Effect of melatonin (75.0 mg/kg) on PTZ induced 
changes in to convulsion behavior of rats. All values are 
mean ± SEM (n = 6). ** More Significant difference at P< 0.01 
vs. Control group (one-way ANOVA followed by Dunnett 
multiple comparison test) 
 
4. DISCUSSION 
The present study demonstrated for the first time the fact 
that melatonin (75 mg/kg) exhibit anti-epileptic activity in 
Pentyleneterazole (PTZ) induced epileptic rats. Wistar albino 
rats of either sex were employed in the present study 
because of their small size, low cost and easily availability.  
Hence, melatonin can perhaps be considered as an adjuvant 
to sodium valproate in the management of epilepsy 
syndrome during PTZ-induced seizure.  
The relation between ion channels and neurotransmitters 
with epilepsy was proved in many epidemiological studies 
(Babb TL et al. 1987). Currently, it is known that reduction of 
GABA level, increase in glutamate level, and alteration in 
sodium or potassium ion channels are observed in the 
population affected from epilepsy syndrome. In our study, 
chemical kindling model of epilepsy was conducted. Kindling 
process refers to a process in which there is a repeated 
administration of a subconvulsant stimulus, electrical or 
chemical produces a gradually increasing 
electroencephalographic and behavioral response which 
culminates in a behavioral seizure. Administration of 
pentylenetetrazole used as an inducing agent at a dose of 25-
55 mg/kg, intraperitoneal in an alternate manner for 20 days 
produced a seizure. 
In the present study, Melatonin (an indoleamine derivative 
of serotonin) at a dose of 75 mg/kg, i.p. was noted to reduce 
hyperexcitability of neurons and thus suppress seizure by 
increasing the level of inhibitory neurotransmitter (GABA). 
Sodium valproate was used as a standard to compare the test 
drugs such as melatonin. 
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